Morphine sulfate solution receives FDA approval

March 2010
Hospice Management Advisor;Mar2010, Vol. 15 Issue 3, p31
The article reports that the morphine sulfate oral solution has been approved by the U.S. Food and Drug Administration (FDA) as pain relief medicine in opioid-tolerant patients. The drug will be available in 100 mg per 5 mL or 20 mg per 1 mL. The oral morphine will be used for moderate to severe, acute and chronic pain in those patients who are not able to swallow tablets. The oral medicine is often used in hospice care.


Related Articles

  • NEW GENERICS.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p77 

    Presents several generic drugs in the U.S. Approval given by the Food and Drug Administration for niacin extended-release tablet from Barr Laboratories; Introduction of oxaprozin tablets by TEVA USA; Dosage form of triamcinolone acetonide from Fougera.

  • Trends in 505(b)(2) Approvals. Gelber, Loren // Contract Pharma;Mar/Apr2010, Vol. 12 Issue 2, p64 

    The article discusses the essentiality of 505(b)(2) new drug application (NDA) was created by the amendments of the Food, Drug and Cosmetic Act of 1984 as approved by the U.S. Food and Drug Administration. It notes the usability of the application to gain approval of alternate dosage forms. It...

  • Current FDA-Related Drug Information. Baker, Danial E. // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p908 

    This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let us know at...

  • Current FDA-Related Drug Information. Baker, Danial E. // Hospital Pharmacy;Jan2007, Vol. 42 Issue 1, p74 

    Several tables are presented that provide information on new drugs approved by the U.S. Food and Drug Administration (FDA), new dosage forms and indications, agents with pending FDA approval and labeling changes related to drug safety.

  • FDA approves new labelling for Embeda.  // Reactions Weekly;Nov2014, Vol. 1525 Issue 1, p1 

    The article focuses on the approval of the U.S. Food and Drug Administration (FDA) for the labelling of morphine or naltrexone (Embeda) capsules.

  • Bioniche Pharma wins FDA approval for generic KetalarCIII.  // PharmaWatch: CNS;Nov2008, Vol. 7 Issue 11, p13 

    The article reports that injectable pharmaceuticals developer and manufacturer Bioniche Pharma Group has obtained the approval from the U.S. Food and Drug Administration (FDA) for its 10mg/ml strength of ketamine hydrochloride injection, the generic equivalent of KetalarCIII. Bioniche's offering...

  • Namenda solution wins FDA approval. Iskowitz, Marc // Medical Marketing & Media;Sep2005, Vol. 40 Issue 9, p10 

    Reports that the Food and Drug Administration has approved an oral solution formulation of Forest Laboratories Inc.'s Namenda.

  • Current FDA-Related Drug Information - New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Significant Labeling Changes or 'Dear Health Professional' Letters Related to Safety Baker, Danial E. // Hospital Pharmacy;Aug2011, Vol. 46 Issue 8, p611 

    Several tables are presented which show various U.S. Food and Drug Administration (FDA)-related drug information including one on the additional drugs approved by the FDA, one on drugs with pending FDA approval, and one on drug license applications filed by drug manufacturers.

  • Rules and Regulations: DEPARTMENT OF HEALTH AND HUMAN SERVICES.  // Federal Register (National Archives & Records Service, Office of;7/15/2013, Vol. 78 Issue 135, p42006 

    The article offers information on the final rule from the U.S. Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) regarding the oral dosage form of new animal drugs including nicarbazin, oclacitinib, and zilpaterol. It says that the FDA amended the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics